Introducing Crowell & Moring’s Government Contractor Recovery Practice Performance Review Offering (PRO)
Client Alert | 1 min read | 03.16.17
The Government Contracts Group of Crowell & Moring LLP is pleased to announce its Government Contractor Recovery Practice, focused on recovery opportunities for our clients in in the government contracting industry. Our team consists of experienced and highly skilled attorney and non-attorney government contract management professionals who stand ready to assist clients with identifying and pursuing claims based on a variety of contractual theories – including REAs and claims to recover (i) increased performance costs attributable to Government action or delay, (ii) costs resulting from Government-initiated contract termination, (iii) costs of remediating certain environmental pollution and toxic tort litigation covered by certain indemnification clauses, and (iv) other costs to which contractors are entitled by operation of contract or statute. Our Performance Review Offering (PRO) allows, at your request, our team of experienced Crowell & Moring attorneys to provide a “diagnostic” review of the relevant documentation on your contract or program and make a recommendation regarding whether or not to pursue a claim; we can also discuss alternative fee arrangements, including risk-sharing, full and partial contingency arrangements.
Contacts
Insights
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
In a somewhat ambiguous press release on Wednesday, June 18, 2025, the Food and Drug Administration (FDA) announced a halt and “immediate review” of new clinical trials where American patients’ cells are sent to China or other “hostile countries” for genetic engineering with the expectation that the cells will be infused back into U.S. patients.[1] A subsequent podcast published by the agency also said that therapies that involved cells that were sent to China for genetic engineering and intended for subsequent infusion into U.S. patients would not be approved going forward. The announcement said that there is “mounting evidence” that some clinical researchers failed to obtain informed consent from trial participants about the international transfer and manipulation of biological material.
Client Alert | 3 min read | 06.26.25
Client Alert | 4 min read | 06.26.25
Ninth Circuit Affirms that CIPA Only Applies to Third-Party Eavesdropping
Client Alert | 4 min read | 06.24.25
CBP Issues First Comprehensive Guide to Modifying a Withhold Release Order (WRO)